No matching results for ''
Tip: Try a valid symbol or a specific company name for relevant results
Canada Markets closed
CANADA WEEKLY BRIEF
STAY UP TO DATE WITH THE MOST IMPORTANT CANADIAN BUSINESS AND FINANCE NEWS
Sign up for the Canada Weekly Brief and get all you need to know delivered right to your inbox
ImmunoGen, Inc. (IMU.F)
Frankfurt - Frankfurt Delayed Price. Currency in EUR
Add to watchlist
At close: 08:02AM CET
2,496 reactions on $IMU.F conversation
Sign in to post a message.
Why is the share price behaving so weak? Management has secured their future by raising cash level to $500m as shareholder expense by showing promising Soraya trial results. What’s up?
First time buyer under 5 today
IMGN has a big year ahead. With $500m cash on hand, can go it alone for 3 years or get acquired for a decent premium.between now and 3 year point. What matters most is progress with clinical trials and success with FDA approvals for 2 lead candidates followed by expanded indications within 1-2 years. Institutions like the risk reward ratio at this price point and are primed with long positions. Selling for past 2 weeks was on low volume and algorithm based to reflect biotech sell off. PT of $9-12 in 2022 is a conservative. Best wishes to all long positions.
Analysts seem bullish on this biotech. About 84% of shares are held by large institutions & mutual funds. A little disturbing that insiders hold such a tiny percentage of the company. Like to see executive management have skin in the game. Hopefully big money is right in their financial support.
This stock got taken to the woodshed today down 9% that’s a lot I know bio is out of favor but most including STRO is only down 2 or 3%
Yes it’s frustrating to see share price dip more than it’s peer group despite recent positive developments. With increased short activity, appears some institutions are shorting their positions to achieve short term options related price targets and/or place pressure on management to sell the company versus try to go it alone. Open to other points of view. How low will it go?
We should finish strong by month's end. Maybe $7's to $8 if living lucky.
Q1 we begin the climb to double digits.
Q2 all hell breaks loose and the dream becomes reality!
Happy Holidays to the longs and believers!
Why doesn't this stock go higher ?? Why is it stuck ?
See everyone at 15 this year very conservative target
Looking forward all the positive developments and announcements in 2022. With close to $500m cash in hand, this stock is primed. Following previous failings, CEO has collaborated well with institutional investors to raise cash and assure a win-win outcome for all stakeholders. Translating lessons learned to future success. Bring on a deja-vu similar to IMMU. Shorts have every reason to get sleepless nights going forward.
$IMGN Orr of 30% $SLS Gps DCR of 87% for Plat Res OC patients. Interesting comparison : "In the platinum-resistant setting and particularly in later-line treated patients, response rates with available therapy are in the single digits with significant toxicities. With an ORR above 30%, a duration of response of around six months, and a treatment-related discontinuation rate below 10%, mirvetuximab shows impressive activity and tolerability for patients with platinum-resistant ovarian cancer. If approved, mirvetuximab will become a critical therapeutic option for patients with FRα-high ovarian cancer."
Look out imgn is on a double digit mission theres no stopping it!
This looks like it will be trading under 5 today I never thought we would be here again after the trial readout but alas here we are again smh in disgust
Down she goes all I ask is get to 8 my break even and I will sell every share of this no good pig of a company and never look back I think every analyst covering this stock would never say this but think they think the management is a joke
One of these days IMGN holders will be treated to what ARNA holders were offered today.
What is big pharma waiting for?
Time for 8’s
Excerpt from the Insider Monkey article:
One of the cheap growth stocks to buy according to Steve Cohen is ImmunoGen, Inc. (NASDAQ:IMGN), a clinical-stage biotechnology firm that develops antibody-drug conjugate cancer therapies. Point72 Asset Management holds 714,700 shares of ImmunoGen, Inc. (NASDAQ:IMGN) worth $4.05 million, accounting for 0.01% of the firm’s total Q3 investments.
ImmunoGen, Inc. (NASDAQ:IMGN) stock was up about 17% by the end of November following the company's promising clinical trial results for mirvetuximab, an experimental ovarian cancer therapy. The Massachusetts-based biotech firm plans to seek approval from the FDA for the cancer drug in Q1 2022. According to Jefferies analyst Kelly Shi, the positive clinical data for mirvetuximab supports ImmunoGen, Inc.'s (NASDAQ:IMGN) MIRASOL potential approval which is anticipated in the third quarter of 2022. On December 1, Shi upgraded ImmunoGen, Inc. (NASDAQ:IMGN) to Buy from Hold rating and increased his price target for the stock to $12 from $7.
At the end of the third quarter, 26 hedge funds in the database of Insider Monkey were bullish on ImmunoGen, Inc. (NASDAQ:IMGN). The total worth of this stake is $363 million.
What`s happening in here...
any news for this stock ?
God am I the only long that’s frustrated with the performance of this stock I don’t understand why it just continues to go lower
IMGN + IQST Fintech + ALPP Drone/EV Parts manuf + FOBIF + AABB
Study: Gas stoves worse for climate than previously thought
The Canadian Press
Tesla rival Rivian's stock could skyrocket at least 160%, says top analyst
CRA to send out new round of letters checking eligibility from CERB recipients
The Canadian Press
© 2022 Yahoo
About Our Ads